---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-25-000019"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T19:01:13.296992+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome

## Summary
- REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.
- Phase 3 PALISADE study showed 80% median triglyceride reduction vs 17% placebo and lower acute pancreatitis incidence.
- REDEMPLO is first FDA-approved siRNA medicine for FCS, self-administered quarterly at home.
- Approximately 6,500 people in the U.S. live with genetic or clinical FCS.
- Arrowhead's first FDA-approved medicine marks transition to a commercial-stage company.

## SEC filing metadata
- accession: 0000879407-25-000019
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/0000879407-25-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940725000019/arwr-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-25-000019
- JSON: https://secwatch.observer/filing/0000879407-25-000019.json
- Plain text: https://secwatch.observer/filing/0000879407-25-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.